Liquidia Stock (NASDAQ:LQDA)
Previous Close
$10.16
52W Range
$6.60 - $16.99
50D Avg
$10.53
200D Avg
$12.35
Market Cap
$851.44M
Avg Vol (3M)
$945.18K
Beta
0.20
Div Yield
-
LQDA Company Profile
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LQDA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GERN | Geron Corporation |
| AMLX | Amylyx Pharmaceuticals, Inc. |
| GOSS | Gossamer Bio, Inc. |
| AGEN | Agenus Inc. |
| BMRN | BioMarin Pharmaceutical Inc. |
| UTHR | United Therapeutics Corporation |
| TECH | Bio-Techne Corporation |
| KALV | KalVista Pharmaceuticals, Inc. |
| MIRM | Mirum Pharmaceuticals, Inc. |
| REPL | Replimune Group, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| LEGN | Legend Biotech Corporation |
| KRON | Kronos Bio, Inc. |
| IMCR | Immunocore Holdings plc |